4 withdrawn, 3 completed, 2 unknown, 1 not yet recruiting. 5 Phase 1, 4 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Not yet recruiting 1, Suspended 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 4 | Withdrawn 3, Unknown 1 |
Follow resiniferatoxin: new trials by email Literature Review of resiniferatoxin trials Research Report on resiniferatoxin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain Resiniferatoxin - Intractable Pain, Palliative Care | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 30 | 2026-11-27 | 2026-10-26 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer Resiniferatoxin, Placebo - Pain, Intractable, Pain Cancer | Phase 2 | Suspended | Sorrento Therapeutics, Inc. | 120 | 2025-09-01 | 2024-03-18 |
| Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain Resiniferatoxin - Morton's Neuroma | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 3 | 2025-03-13 | 2026-04-13 |
| Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis Resiniferatoxin, Zilretta, Placebo - Osteoarthritis, Knee, Knee Osteoarthritis | Phase 2 | Unknown | Sorrento Therapeutics, Inc. | 124 | 2021-11-15 | 2023-01-17 |
| Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed Resiniferatoxin, Placebo - Osteoarthritis, Knee, Osteo Arthritis Knee | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-04-01 | 2021-11-09 | |
| Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain Resiniferatoxin, Standard of Care - Pain, Intractable, Pain Cancer | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2020-12-01 | 2021-11-09 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee Resiniferatoxin, Placebo - Osteoarthritis, Knee, Knee Pain Chronic | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2020-12-01 | 2021-11-09 | |
| Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis Resiniferatoxin, Saline - Osteoarthritis, Knee, Pain, Knee | Phase 1 | Completed | Sorrento Therapeutics, Inc. | 94 | 2018-07-12 | 2021-04-01 |
| Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain Resiniferatoxin - Intractable Cancer Pain | Phase 1 | Completed | Sorrento Therapeutics, Inc. | 17 | 2017-09-01 | 2020-10-20 |
| DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients DEX Combined With RTX, CSA and IVIG - Immune Thrombocytopenia | Phase 3 | Unknown | Shandong University | 100 | 2016-06-01 | 2016-07-15 |
| Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency Rituximab (RTX) and Azathioprine (AZA), Placebos - Granulomatous and Lymphocytic Interstitial Lung Disease | Phase 2 | Withdrawn | Medical College of Wisconsin | 2016-05-02 | 2020-03-10 |
Cancer Pain (4) · Osteoarthritis, Knee (4) · Pain (3) · Pain, Intractable (3) · Osteoarthritis (2) · Common Variable Immunodeficiency (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Morton Neuroma (1) · Primary Immunodeficiency Diseases (1)
Sorrento Therapeutics, Inc. (7) · Medical College of Wisconsin (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · National Institutes of Health Clinical Center (CC) (1) · Paolo Caimi, MD (1) · Shandong University (1)
United States (7) · China (1)
Monica Luchi, MD (5) · Mike Royal, MD (2) · Andrew J Mannes, M.D. (1) · John D Heiss, M.D. (1) · John M Routes, MD (1) · Ming Hou (1) · Paolo Caimi, MD (1)